
Venrock Adviser, LLC
About Venrock Adviser, LLC’s 13F portfolio
Venrock Adviser, LLC is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Venrock Adviser, LLC reported $3.3B across 33 US-listed positions (). Its largest position is APOGEE THERAPEUTICS INC (APGE) at 34% of the reported book, and its ten biggest holdings make up 80% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: APGE APOGEE THERAPEUTICS INC | — — | 34% | 8.5M | $1.1B |
| 2 | NASDAQ: ORKA ORUKA THERAPEUTICS INC | — — | 12% | 4.1M | $394.8M |
| 3 | NASDAQ: ERAS ERASCA INC | — — | 9.9% | 17.9M | $327.8M |
| 4 | NASDAQ: SYRE SPYRE THERAPEUTICS INC | — — | 8.0% | 3.0M | $265.0M |
| 5 | NASDAQ: DNTH DIANTHUS THERAPEUTICS INC | — — | 3.5% | 1.2M | $115.0M |
| 6 | NASDAQ: OCUL OCULAR THERAPEUTIX INC | — — | 3.1% | 10.3M | $101.6M |
| 7 | NASDAQ: DMRA DAMORA THERAPEUTICS INC | — — | 2.8% | 3.6M | $93.7M |
| 8 | NASDAQ: SVRA SAVARA INC | — — | 2.8% | 14.7M | $90.8M |
| 9 | NASDAQ: JBIO JADE BIOSCIENCES INC | — — | 2.2% | 3.2M | $71.6M |
| 10 | NASDAQ: COGT COGENT BIOSCIENCES INC | — — | 1.9% | 1.6M | $63.6M |
| 11 | NASDAQ: VRDN VIRIDIAN THERAPEUTICS INC | — — | 1.8% | 3.3M | $59.8M |
| 12 | NASDAQ: VOR VOR BIOPHARMA INC | — — | 1.7% | 3.0M | $56.0M |
| 13 | NASDAQ: DYN DYNE THERAPEUTICS INC | — — | 1.5% | 2.2M | $48.3M |
| 14 | NASDAQ: MAZE MAZE THERAPEUTICS INC | — — | 1.4% | 1.6M | $47.8M |
| 15 | NASDAQ: RLMD RELMADA THERAPEUTICS INC | — — | 1.4% | 6.8M | $47.4M |
| 16 | NASDAQ: ORIC ORIC PHARMACEUTICALS INC | — — | 1.4% | 4.3M | $46.8M |
| 17 | NASDAQ: CBIO CRESCENT BIOPHARMA INC. | — — | 1.2% | 2.1M | $38.4M |
| 18 | NASDAQ: ZURA ZURA BIO LTD | — — | 1.2% | 6.4M | $38.0M |
| 19 | NASDAQ: ANL ADLAI NORTYE LTD | — — | 1.1% | 3.2M | $36.9M |
| 20 | NASDAQ: ELVN ENLIVEN THERAPEUTICS INC | — — | 0.8% | 526K | $26.7M |
| 21 | NASDAQ: HELP CYBIN INC | — — | 0.8% | 3.9M | $25.5M |
| 22 | NASDAQ: CGEM CULLINAN THERAPEUTICS INC | — — | 0.8% | 1.4M | $25.1M |
| 23 | NASDAQ: IPSC CENTURY THERAPEUTICS INC | — — | 0.6% | 8.7M | $21.3M |
| 24 | NASDAQ: ARTV ARTIVA BIOTHERAPEUTICS INC | — — | 0.6% | 2.0M | $19.8M |
| 25 | NASDAQ: CTMX CYTOMX THERAPEUTICS INC | — — | 0.6% | 5.0M | $18.7M |
Showing 1–25 of 33 positions on this page reported in this 13F.
- Healthcare96%
- AddedERASERASCA INC+9.2%$327.8M
- AddedSVRASAVARA INC+7.3%$90.8M
- AddedRLMDRELMADA THERAPEUTICS INC+41.3%$47.4M
- AddedARTVARTIVA BIOTHERAPEUTICS INC+27.0%$19.8M
- NewACHVACHIEVE LIFE SCIENCE INC—$18.0M
- NewPBLSPARABILIS MEDICINES INC—$17.1M
- AddedXFORX4 PHARMACEUTICALS INC+485%$9.0M
- NewRACCRESEARCH ALLIANCE CORP III—$3.2M
- NewINMINMED PHARMACEUTICALS INC—$51K
- ReducedSYRESPYRE THERAPEUTICS INC−19.0%$265.0M
- ReducedCOGTCOGENT BIOSCIENCES INC−17.9%$63.6M
- ReducedVRDNVIRIDIAN THERAPEUTICS INC−16.1%$59.8M
- ReducedELVNENLIVEN THERAPEUTICS INC−69.5%$26.7M
- ReducedCTMXCYTOMX THERAPEUTICS INC−50.1%$18.7M
- SoldKALVKALVISTA PHARMACEUTICALS INC−100%—
- SoldENGNENGENE HOLDINGS INC−100%—
- SoldSEPNSEPTERNA INC−100%—
- SoldTENXTENAX THERAPEUTICS INC−100%—
Reading Venrock Adviser, LLC’s 13F portfolio
Venrock Adviser, LLC’s $3.3B 13F book is spread across 33 reported positions and is highly concentrated — its ten largest positions alone are 80% of the portfolio. A book this concentrated means a small group of names drives most of its performance. Its five largest positions are APGE, ORKA, ERAS, SYRE and DNTH, led by APOGEE THERAPEUTICS INC (APGE) at 34% of the portfolio. The heaviest sector exposure is Healthcare (96%).
What Venrock Adviser, LLC changed last quarter
Between 2026-03-31 and Q2 2026, Venrock Adviser, LLC was roughly balanced between buying and selling: it opened 4 new positions and added to 5 more, while trimming 5 and closing 4 outright. Against a 33-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was ERASCA INC (ERAS), and its biggest reduction was SPYRE THERAPEUTICS INC (SYRE).
What a 13F does and doesn’t reveal
A 13F captures only Venrock Adviser, LLC’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Venrock Adviser, LLC is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Venrock Adviser, LLC's profile on this page is built directly from those filings.
How current is the 13F data on Venrock Adviser, LLC's page?
It reflects Venrock Adviser, LLC's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Venrock Adviser, LLC files its next quarterly report, this page refreshes automatically.
Can I see Venrock Adviser, LLC's complete list of holdings?
This page highlights Venrock Adviser, LLC's largest positions rather than all 33 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Venrock Adviser, LLC's filings.
Does a 13F show everything Venrock Adviser, LLC owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Venrock Adviser, LLC's book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Venrock Adviser, LLC made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

